Xcout Intel
Jade Biosciences, Inc.
Jade Biosciences, Inc. operates as a biotechnology enterprise, primarily focused on pioneering superior therapeutic solutions for significant unmet medical requirements in autoimmune disorders. Its leading development candidate, JADE-001, specifically targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway, aiming to treat immunoglobulin A (IgA) nephropathy. Clinical trials for JADE-001 are slated to commence in the latter half of 2025, with initial results projected for the first half of 2026. Beyond this lead asset, the company's robust pipeline includes two preclinical antibody programs, JADE-002 and JADE-003.
Subscribe to see Jade Biosciences, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Jade Biosciences, Inc. at a glance
Jade Biosciences, Inc. is a biotechnology company headquartered in Waltham, United States. It is publicly listed (JBIO) with a market capitalisation of $856.7M. Xcout tracks 16 named people at Jade Biosciences, Inc., including Tom Frohlich (President, CEO & Director). Xcout recorded 18 job postings from Jade Biosciences, Inc. in the last 90 days.
Jade Biosciences, Inc. leadership
- Tom FrohlichPresident, CEO & Director
- Andrew James KingPresident of Research & Development
- Bradford D. DahmsCFO & Treasurer
- Edward R. ConnerChief Medical Officer
- Elizabeth BaltaChief Legal Officer & Corporate Secretary
- Amy SullivanSenior Vice President of Development Operations
10 more named people on record for Jade Biosciences, Inc., with roles, board committees and tenure — see the full roster →
Hiring at Jade Biosciences, Inc.
Xcout recorded 18 job postings from Jade Biosciences, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see Jade Biosciences, Inc.'s hiring signals →
Jade Biosciences, Inc. competitors
A few of Jade Biosciences, Inc.'s closest competitors — see the full list of competitors and alternatives →
ImageneBio Inc (IMA) is a biotechnology company with therapies currently undergoing human trials. The firm concentrates on creating innovative medical treatments for a variety of immune-related and inflammatory diseases. A key component of their pipeline is IMG-007, a non-depleting anti-OX40 monoclonal antibody, which is now in Phase 2b clinical studies targeting atopic dermatitis.
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
Human Immunology Biosciences was a U.S. biotechnology company developing targeted immunotherapies for serious immune-mediated diseases. Its lead asset was felzartamab, an anti-CD38 monoclonal antibody being studied in conditions including IgA nephropathy and membranous nephropathy; Novartis acquired the company in 2024.
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
XORTX Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney diseases, including specific pipeline candidates for gout and other conditions.
R1 Therapeutics is a renal-focused biotech company developing innovative, first-in-class, category-defining therapeutics for patients with kidney disease. Headquartered in San Francisco with additional offices in San Diego and Raleigh, the company started with lead asset AP306.
Get Jade Biosciences, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Jade Biosciences, Inc.? Suggest a correction
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Jade Biosciences, Inc. in Xcout Intel
- 16 named people with titles, LinkedIn and board committees
- Weekly hiring history and the mix of roles behind it
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access